Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)


You May Also Like

US Department of Defense Research Collaboration Moves Forward

Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completedStudies commissioned ...

Global Precision Medicine Market Report 2017-2026

Dublin, Oct. 24, 2017 (GLOBE NEWSWIRE) -- The "Global Precision Medicine Market" report has ...